Adjunctive therapies for severe sepsis
Abstract Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2008-11, Vol.32, p.S34-S38 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S38 |
|---|---|
| container_issue | |
| container_start_page | S34 |
| container_title | International journal of antimicrobial agents |
| container_volume | 32 |
| creator | Wittebole, X Collienne, C Castanares-Zapatero, D Laterre, P.F |
| description | Abstract Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications should be better defined by ongoing trials. Use of low-dose steroids for the treatment of severe sepsis must be re-clarified by new studies and should be restricted to patients with refractory septic shock. Trials exploring the role of natural anticoagulants and Toll-like receptor inhibitors are ongoing and should be completed in the coming 3 years. Future trials in severe sepsis should target more homogeneous populations with a well-defined focus of infection and severity, receiving appropriate standard of care, and the tested intervention should be administered in a timely fashion according to the expected host response. |
| doi_str_mv | 10.1016/j.ijantimicag.2008.06.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69924485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0924857908002483</els_id><sourcerecordid>69924485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-340c4664949456c585b49f9609373a96e4db0ffe0070236a5eb7ef9c0b2acbe03</originalsourceid><addsrcrecordid>eNqNkU1P3DAQhq2qqGyBv4C2h3JLOo4_El8qoRUUJKQeaM-W40zAIZtsPclK_Hu82hVUnJAPM4dnXtvPMPaNQ86B6x9dHjo3TGEdvHvIC4AqB50DqE9swauyyErDxWe2AFPIrFKlOWZfiToAroRUX9hxgrgqVbVgF5dNNw9-CltcTo8Y3SYgLdsxLgm3GDGVDQU6ZUet6wnPDvWE_b2--rO6ye5-_7pdXd5lXmqYMiEhNVqadJT2qlK1NK3RYEQpnNEomxraFgFKKIR2CusSW-OhLpyvEcQJu9jnbuL4b0aa7DqQx753A44zWW3Sl2SlEmj2oI8jUcTWbmJYu_hsOdidJNvZ_yTZnSQL2iZJafb8cMlcr7F5mzxYScD3A-DIu76NbvCBXrkCKp3yZOJWew6Tkm3AaMkHHDw2IaKfbDOGDz3n57sU34chYf0TPiN14xyH5NxyS4UFe7_b6m6pUAGkTogXjqCesA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69924485</pqid></control><display><type>article</type><title>Adjunctive therapies for severe sepsis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wittebole, X ; Collienne, C ; Castanares-Zapatero, D ; Laterre, P.F</creator><creatorcontrib>Wittebole, X ; Collienne, C ; Castanares-Zapatero, D ; Laterre, P.F</creatorcontrib><description>Abstract Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications should be better defined by ongoing trials. Use of low-dose steroids for the treatment of severe sepsis must be re-clarified by new studies and should be restricted to patients with refractory septic shock. Trials exploring the role of natural anticoagulants and Toll-like receptor inhibitors are ongoing and should be completed in the coming 3 years. Future trials in severe sepsis should target more homogeneous populations with a well-defined focus of infection and severity, receiving appropriate standard of care, and the tested intervention should be administered in a timely fashion according to the expected host response.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2008.06.005</identifier><identifier>PMID: 18715758</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Anti-Infective Agents - therapeutic use ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Anticoagulants ; Anticoagulants - therapeutic use ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Drotrecogin alfa (activated) ; Drug Therapy, Combination ; Human bacterial diseases ; Humans ; Immunosuppressive Agents - therapeutic use ; Infectious Disease ; Infectious diseases ; Medical sciences ; Pharmacology. Drug treatments ; Protein C - therapeutic use ; Recombinant Proteins - therapeutic use ; Sepsis - drug therapy ; Severe sepsis ; Steroids ; Steroids - therapeutic use</subject><ispartof>International journal of antimicrobial agents, 2008-11, Vol.32, p.S34-S38</ispartof><rights>Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2008 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-340c4664949456c585b49f9609373a96e4db0ffe0070236a5eb7ef9c0b2acbe03</citedby><cites>FETCH-LOGICAL-c460t-340c4664949456c585b49f9609373a96e4db0ffe0070236a5eb7ef9c0b2acbe03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2008.06.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20862004$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18715758$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wittebole, X</creatorcontrib><creatorcontrib>Collienne, C</creatorcontrib><creatorcontrib>Castanares-Zapatero, D</creatorcontrib><creatorcontrib>Laterre, P.F</creatorcontrib><title>Adjunctive therapies for severe sepsis</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Abstract Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications should be better defined by ongoing trials. Use of low-dose steroids for the treatment of severe sepsis must be re-clarified by new studies and should be restricted to patients with refractory septic shock. Trials exploring the role of natural anticoagulants and Toll-like receptor inhibitors are ongoing and should be completed in the coming 3 years. Future trials in severe sepsis should target more homogeneous populations with a well-defined focus of infection and severity, receiving appropriate standard of care, and the tested intervention should be administered in a timely fashion according to the expected host response.</description><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Drotrecogin alfa (activated)</subject><subject>Drug Therapy, Combination</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein C - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Sepsis - drug therapy</subject><subject>Severe sepsis</subject><subject>Steroids</subject><subject>Steroids - therapeutic use</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1P3DAQhq2qqGyBv4C2h3JLOo4_El8qoRUUJKQeaM-W40zAIZtsPclK_Hu82hVUnJAPM4dnXtvPMPaNQ86B6x9dHjo3TGEdvHvIC4AqB50DqE9swauyyErDxWe2AFPIrFKlOWZfiToAroRUX9hxgrgqVbVgF5dNNw9-CltcTo8Y3SYgLdsxLgm3GDGVDQU6ZUet6wnPDvWE_b2--rO6ye5-_7pdXd5lXmqYMiEhNVqadJT2qlK1NK3RYEQpnNEomxraFgFKKIR2CusSW-OhLpyvEcQJu9jnbuL4b0aa7DqQx753A44zWW3Sl2SlEmj2oI8jUcTWbmJYu_hsOdidJNvZ_yTZnSQL2iZJafb8cMlcr7F5mzxYScD3A-DIu76NbvCBXrkCKp3yZOJWew6Tkm3AaMkHHDw2IaKfbDOGDz3n57sU34chYf0TPiN14xyH5NxyS4UFe7_b6m6pUAGkTogXjqCesA</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Wittebole, X</creator><creator>Collienne, C</creator><creator>Castanares-Zapatero, D</creator><creator>Laterre, P.F</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>Adjunctive therapies for severe sepsis</title><author>Wittebole, X ; Collienne, C ; Castanares-Zapatero, D ; Laterre, P.F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-340c4664949456c585b49f9609373a96e4db0ffe0070236a5eb7ef9c0b2acbe03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Drotrecogin alfa (activated)</topic><topic>Drug Therapy, Combination</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein C - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Sepsis - drug therapy</topic><topic>Severe sepsis</topic><topic>Steroids</topic><topic>Steroids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wittebole, X</creatorcontrib><creatorcontrib>Collienne, C</creatorcontrib><creatorcontrib>Castanares-Zapatero, D</creatorcontrib><creatorcontrib>Laterre, P.F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wittebole, X</au><au>Collienne, C</au><au>Castanares-Zapatero, D</au><au>Laterre, P.F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjunctive therapies for severe sepsis</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>32</volume><spage>S34</spage><epage>S38</epage><pages>S34-S38</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Abstract Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications should be better defined by ongoing trials. Use of low-dose steroids for the treatment of severe sepsis must be re-clarified by new studies and should be restricted to patients with refractory septic shock. Trials exploring the role of natural anticoagulants and Toll-like receptor inhibitors are ongoing and should be completed in the coming 3 years. Future trials in severe sepsis should target more homogeneous populations with a well-defined focus of infection and severity, receiving appropriate standard of care, and the tested intervention should be administered in a timely fashion according to the expected host response.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>18715758</pmid><doi>10.1016/j.ijantimicag.2008.06.005</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2008-11, Vol.32, p.S34-S38 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69924485 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Anti-Infective Agents - therapeutic use Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Anticoagulants Anticoagulants - therapeutic use Bacterial diseases Bacterial sepsis Biological and medical sciences Drotrecogin alfa (activated) Drug Therapy, Combination Human bacterial diseases Humans Immunosuppressive Agents - therapeutic use Infectious Disease Infectious diseases Medical sciences Pharmacology. Drug treatments Protein C - therapeutic use Recombinant Proteins - therapeutic use Sepsis - drug therapy Severe sepsis Steroids Steroids - therapeutic use |
| title | Adjunctive therapies for severe sepsis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A12%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjunctive%20therapies%20for%20severe%20sepsis&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Wittebole,%20X&rft.date=2008-11-01&rft.volume=32&rft.spage=S34&rft.epage=S38&rft.pages=S34-S38&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2008.06.005&rft_dat=%3Cproquest_cross%3E69924485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69924485&rft_id=info:pmid/18715758&rft_els_id=1_s2_0_S0924857908002483&rfr_iscdi=true |